176 related articles for article (PubMed ID: 8630640)
1. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers.
Patoia L; Santucci L; Furno P; Dionisi MS; Dell'Orso S; Romagnoli M; Sattarinia A; Marini MG
Br J Rheumatol; 1996 Apr; 35 Suppl 1():61-7. PubMed ID: 8630640
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study.
Lipscomb GR; Wallis N; Armstrong G; Rees WD
Br J Clin Pharmacol; 1998 Aug; 46(2):133-7. PubMed ID: 9723821
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis.
Chang DM; Young TH; Hsu CT; Kuo SY; Hsieh TC
Clin Rheumatol; 2001; 20(2):104-13. PubMed ID: 11346221
[TBL] [Abstract][Full Text] [Related]
4. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip.
Lindén B; Distel M; Bluhmki E
Br J Rheumatol; 1996 Apr; 35 Suppl 1():35-8. PubMed ID: 8630634
[TBL] [Abstract][Full Text] [Related]
5. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
Dequeker J; Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Isomäki H; Littlejohn G; Mau J; Papazoglou S
Br J Rheumatol; 1998 Sep; 37(9):946-51. PubMed ID: 9783758
[TBL] [Abstract][Full Text] [Related]
6. Comparison of endoscopic gastric mucosa features after administration of piroxicam to meloxicam and their correlation with dyspepsia symptoms in elderly patient with knee osteoarthritis.
Girawan D; Abdurachman SA; Djumhana A; Roslia J; Pramudiyo R
Acta Med Indones; 2004; 36(4):202-6. PubMed ID: 15673949
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study.
Carrabba M; Paresce E; Angelini M; Galanti A; Marini MG; Cigarini P
Curr Med Res Opin; 1995; 13(6):343-55. PubMed ID: 8829892
[TBL] [Abstract][Full Text] [Related]
8. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial.
Dougados M; Gueguen A; Nakache JP; Velicitat P; Veys EM; Zeidler H; Calin A
Rheumatology (Oxford); 1999 Mar; 38(3):235-44. PubMed ID: 10325662
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis.
Ghozlan PR; Bernhardt M; Vélicitat P; Bluhmki E
Br J Rheumatol; 1996 Apr; 35 Suppl 1():51-5. PubMed ID: 8630638
[TBL] [Abstract][Full Text] [Related]
10. Review of clinical trials and benefit/risk ratio of meloxicam.
Barner A
Scand J Rheumatol Suppl; 1996; 102():29-37. PubMed ID: 8628979
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: a comparison with intramuscular and oral piroxicam.
Bosch HC; Sigmund R; Hettich M
Curr Med Res Opin; 1997; 14(1):29-38. PubMed ID: 9524791
[TBL] [Abstract][Full Text] [Related]
12. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam.
Singh G; Lanes S; Triadafilopoulos G
Am J Med; 2004 Jul; 117(2):100-6. PubMed ID: 15234645
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease.
Degner F; Sigmund R; Zeidler H
Clin Ther; 2000 Apr; 22(4):400-10. PubMed ID: 10823362
[TBL] [Abstract][Full Text] [Related]
14. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis.
Wojtulewski JA; Schattenkirchner M; Barceló P; Le Loët X; Bevis PJ; Bluhmki E; Distel M
Br J Rheumatol; 1996 Apr; 35 Suppl 1():22-8. PubMed ID: 8630632
[TBL] [Abstract][Full Text] [Related]
15. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial.
Rinder HM; Tracey JB; Souhrada M; Wang C; Gagnier RP; Wood CC
J Clin Pharmacol; 2002 Aug; 42(8):881-6. PubMed ID: 12162470
[TBL] [Abstract][Full Text] [Related]
16. Safety of meloxicam: a global analysis of clinical trials.
Distel M; Mueller C; Bluhmki E; Fries J
Br J Rheumatol; 1996 Apr; 35 Suppl 1():68-77. PubMed ID: 8630641
[TBL] [Abstract][Full Text] [Related]
17. Piroxicam-beta-cyclodextrin: effects on gastrointestinal blood loss and gastric mucosal appearance in healthy men.
Warrington S; Debbas N; Farthing M; Horton M; Umile A
Int J Tissue React; 1991; 13(5):243-8. PubMed ID: 1806546
[TBL] [Abstract][Full Text] [Related]
18. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac.
Furst DE; Kolba KS; Fleischmann R; Silverfield J; Greenwald M; Roth S; Hall DB; Roszko PJ;
J Rheumatol; 2002 Mar; 29(3):436-46. PubMed ID: 11908554
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee.
Lund B; Distel M; Bluhmki E
Scand J Rheumatol; 1998; 27(1):32-7. PubMed ID: 9506875
[TBL] [Abstract][Full Text] [Related]
20. Meloxicam.
Noble S; Balfour JA
Drugs; 1996 Mar; 51(3):424-30; discussion 431-32. PubMed ID: 8882380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
